Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2977-2986

  Amrein, Philip C ^a,d   Attar, Eyal C ^a,d   Takvorian, Tak ^a,d   Hochberg, Ephraim P ^a,d   Ballen, Karen K ^a,d   Leahy, Kathleen M ^a   Fisher, David C ^b,d   LaCasce, Ann S ^b,d   Jacobsen, Eric D ^b,d   Armand, Philippe ^b,d   Hasserjian, Robert P ^c   Werner, Lillian ^b   Neuberg, Donna ^b   Brown, Jennifer R ^b,d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EARLY GROWTH RESPONSE FACTOR 1; FK 506 BINDING PROTEIN; FLUDARABINE; NOTCH2 RECEPTOR; PROTEIN KINASE SYK;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENZYME ACTIVATION; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEARTBURN; HUMAN; INFECTION; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REFRACTORY PERIOD; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; VOMITING; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PYRIMIDINES; RADIOGRAPHY, ABDOMINAL; RECURRENCE; THIAZOLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955513805     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2879     Document Type: Article

References (32)

1. Zweibel J, Ho P, Sepelak SB, Saunders J, Cheson BD, Nelson A. Clinical trials referral resource. Clinical trials with perillyl alcohol. Oncology (Williston Park) 1997;11:1817, 1820.
2. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-8. (Pubitemid 46211312)
3. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62. (Pubitemid 34874007)
4. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:2033-9. (Pubitemid 34270057)
5. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
6. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-78. (Pubitemid 40385478)
7. Allsup DJ, Kamiguti AS, Lin K, Sherrington PD, Matrai Z, Slupsky JR, et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005;65:7328-37. (Pubitemid 41161265)
8. Gobessi S, Laurenti L. Constitutive activation of the protein tyrosine kinase Syk in chronic lymphocytic leukemia B-cells. Blood 2007;110: abstr 1123.
9. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-55.
10. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401. (Pubitemid 38938156)
11. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-52.
12. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. Crystal structures of the Lyn protein tyrosine kinase domain in its Apoand inhibitor-bound state. J Biol Chem 2009;284:284-91.
13. Donato N, Wu J. The SRC/ABL inhibitor BMS-354825 overcomes resistance to imatinib mesylate in chronic myelogenous leukemia cells through multiple mechanisms. Blood (abstract) 2004;104:abstr 1989.
14. Talpaz M, Kantarjian H. Hematologic and cytogenetic responses in imatinib-resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Blood 2004;104:abstr 20.
15. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9.
16. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
17. Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009;49:700-9.
18. Ruddy KJ, Wu D, Brown JR. Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol 2008;26:2781-2.
19. Pitini V, Arrigo C, Altavilla G. Dasatinib induces a response in chronic lymphocytic leukemia. Blood 2009;113:498.
20. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
21. Ren CL, Morio T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 1994;179:673-80. (Pubitemid 24058755)
22. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141-9.
23. Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008;143:698-706.
24. Wang Y, Song Z. Activity of SYK and PLCg2 predict apoptotic response of chronic lymphocytic leukemia cells to SRC tyrosine kinasae inhibitor dasatinib. Blood 2009;114:abstr 1249.
25. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
26. Romano S, Mallardo M, Chiurazzi F, Bisogni R, D'Angelillo A, Liuzzi R, et al. The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells. Haematologica 2008;93:1039-48. (Pubitemid 351957021)
27. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 2001;91:474-80. (Pubitemid 32115100)
28. Conti BJ, Davis BK, Zhang J, O'Connor W Jr., Williams KL, Ting JP. CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. J Biol Chem 2005; 280: 18375-85. (Pubitemid 41389086)
29. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in BCLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005;19:260-7. (Pubitemid 40220591)
30. Frey UH, Nuckel H, Sellmann L, Siemer D, Kuppers R, Durig J, et al. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006;12:5686-92. (Pubitemid 44629596)
31. Kaderi MA, Murray F, Jansson M, Merup M, Karlsson K, Roos G, et al. The GNAS1 T393C polymorphismand lack of clinical prognostic value in chronic lymphocytic leukemia. Leuk Res 2008;32:984-7. (Pubitemid 351389548)
32. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, et al. NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 2003;17:1349-56. (Pubitemid 36857343)